Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Added to Standard of Care Following Hospitalization for a COPD Exacerbation
NCT07587658Phase 4Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2026
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of dupilumab in chronic obstructive pulmonary disease (COPD), sponsored by Regeneron Pharmaceuticals. Started Oct 2026; status: recruiting.
02
Drugs
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07587658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587658.